Literature DB >> 22024523

Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C.

Takeji Umemura1, Satoru Joshita, Suguru Yoneda, Yoshihiko Katsuyama, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Masao Ota, Eiji Tanaka.   

Abstract

BACKGROUND: Both IL28B gene polymorphisms and serum levels of interleukin (IL)-10, IL-12p40 and IL-18 have been reported to affect the outcome of natural and pegylated interferon and ribavirin-treated HCV infection.
METHODS: To clarify their association and predictive value in treatment outcome of genotype 1 HCV-infected patients, we measured pretreatment serum IL-10, IL-12p40 and IL-18 levels using multiplex assays and determined IL28B gene polymorphisms (rs 8099917) in 52 cases with chronic hepatitis C.
RESULTS: High baseline levels of IL-10 (P<0.001) and low levels of IL-12p40 (P<0.001) were significantly associated with a non-virological response (NVR) in our cohort. The IL28B polymorphism was tested and TT, TG or GG genotypes were found in 60%, 38% and 2% of patients, respectively, with corresponding NVR rates of 10%, 60% and 100% (P<0.001). Serum cytokine levels were significantly correlated with IL28B gene polymorphisms. When serum IL-10 levels were stratified at 5.0 pg/ml, NVR rates were 50% versus 0% (P=0.004) for the TT genotype and 87% versus 0% (P=0.001) for the TG or GG genotypes. Similarly, low IL-12p40 levels were associated with an NVR in patients with TG or GG genotypes (P=0.006). In multivariate analysis, high IL-10, low IL-12p40 and IL28B TG or GG genotypes were independently associated with an NVR.
CONCLUSIONS: Serum IL-10 and IL-12p40 levels in combination with IL28B genotype, especially G-allele carriage, are strong predictive markers of an NVR to HCV treatment with pegylated interferon and ribavirin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024523     DOI: 10.3851/IMP1869

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  13 in total

Review 1.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

2.  Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.

Authors:  Zhifang Jia; Yanhua Ding; Suyan Tian; Junqi Niu; Jing Jiang
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

3.  Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.

Authors:  Verónica Saludes; Elisabet Bascuñana; Elena Jordana-Lluch; Sònia Casanovas; Mercè Ardèvol; Esther Soler; Ramón Planas; Vicente Ausina; Elisa Martró
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

Review 4.  Signal transducer and activator of transcription 4 in liver diseases.

Authors:  Yan Wang; Aijuan Qu; Hua Wang
Journal:  Int J Biol Sci       Date:  2015-02-27       Impact factor: 6.580

5.  IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C.

Authors:  Benjamin Krämer; Claudia Finnemann; Beatriz Sastre; Philipp Lutz; Andreas Glässner; Franziska Wolter; Felix Goeser; Pavlos Kokordelis; Dominik Kaczmarek; Hans-Dieter Nischalke; Christian P Strassburg; Ulrich Spengler; Jacob Nattermann
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

6.  Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.

Authors:  Ming-Ying Lu; Ching-I Huang; Chia-Yen Dai; Shu-Chi Wang; Ming-Yen Hsieh; Meng-Hsuan Hsieh; Po-Cheng Liang; Yi-Hung Lin; Nai-Jen Hou; Ming-Lun Yeh; Chung-Feng Huang; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Wan-Long Chuang; Ming-Lung Yu
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

7.  Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.

Authors:  Gabriella Par; Laszlo Szereday; Timea Berki; Laszlo Palinkas; Melinda Halasz; Attila Miseta; Geza Hegedus; Julia Szekeres-Bartho; Aron Vincze; Bela Hunyady; Alajos Par
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

8.  KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.

Authors:  Yuichi Nozawa; Takeji Umemura; Satoru Joshita; Yoshihiko Katsuyama; Soichiro Shibata; Takefumi Kimura; Susumu Morita; Michiharu Komatsu; Akihiro Matsumoto; Eiji Tanaka; Masao Ota
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

9.  The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome.

Authors:  Joanna Jabłońska; Tomasz Pawłowski; Tomasz Laskus; Małgorzata Zalewska; Małgorzata Inglot; Sylwia Osowska; Karol Perlejewski; Iwona Bukowska-Ośko; Kamila Caraballo Cortes; Agnieszka Pawełczyk; Piotr Ząbek; Marek Radkowski
Journal:  BMC Infect Dis       Date:  2015-12-04       Impact factor: 3.090

10.  Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.

Authors:  Tomoo Yamazaki; Satoru Joshita; Takeji Umemura; Yoko Usami; Ayumi Sugiura; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Koji Igarashi; Masao Ota; Eiji Tanaka
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.